HK1158634A1 - Novel compounds useful for the treatment of degenerative and inflammatory diseases - Google Patents
Novel compounds useful for the treatment of degenerative and inflammatory diseasesInfo
- Publication number
- HK1158634A1 HK1158634A1 HK11112985.9A HK11112985A HK1158634A1 HK 1158634 A1 HK1158634 A1 HK 1158634A1 HK 11112985 A HK11112985 A HK 11112985A HK 1158634 A1 HK1158634 A1 HK 1158634A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diseases
- disease
- treatment
- cartilage
- involving
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000003412 degenerative effect Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 239000002158 endotoxin Substances 0.000 abstract 2
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000003456 Juvenile Arthritis Diseases 0.000 abstract 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- -1 [1,2,4]triazolo[1,5-a]pyridine compound Chemical class 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000008355 cartilage degradation Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 210000001612 chondrocyte Anatomy 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000007306 turnover Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13592008P | 2008-07-25 | 2008-07-25 | |
US22068509P | 2009-06-26 | 2009-06-26 | |
PCT/EP2009/059605 WO2010010191A1 (en) | 2008-07-25 | 2009-07-24 | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1158634A1 true HK1158634A1 (en) | 2012-07-20 |
Family
ID=41021059
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11112985.9A HK1158634A1 (en) | 2008-07-25 | 2011-11-30 | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
HK11112990.2A HK1158635A1 (en) | 2008-07-25 | 2011-11-30 | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11112990.2A HK1158635A1 (en) | 2008-07-25 | 2011-11-30 | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
Country Status (36)
Country | Link |
---|---|
US (5) | US8853240B2 (xx) |
EP (2) | EP2361251B1 (xx) |
JP (2) | JP5559168B2 (xx) |
KR (2) | KR101711911B1 (xx) |
CN (2) | CN102105471B (xx) |
AR (1) | AR072875A1 (xx) |
AU (2) | AU2009273143B2 (xx) |
BR (2) | BRPI0916659B8 (xx) |
CA (2) | CA2730757A1 (xx) |
CL (1) | CL2009001637A1 (xx) |
CO (1) | CO6361925A2 (xx) |
CR (1) | CR20110092A (xx) |
CY (2) | CY1113945T1 (xx) |
DK (2) | DK2346864T3 (xx) |
DO (1) | DOP2011000022A (xx) |
EA (2) | EA018080B1 (xx) |
ES (2) | ES2406691T3 (xx) |
HK (2) | HK1158634A1 (xx) |
HR (2) | HRP20130357T1 (xx) |
IL (2) | IL210261A (xx) |
JO (1) | JO3041B1 (xx) |
MA (1) | MA32551B1 (xx) |
ME (1) | ME02046B (xx) |
MX (2) | MX2011000758A (xx) |
MY (1) | MY157615A (xx) |
NZ (1) | NZ590646A (xx) |
PE (1) | PE20100152A1 (xx) |
PL (2) | PL2346864T3 (xx) |
PT (2) | PT2346864E (xx) |
RS (2) | RS53406B (xx) |
SI (2) | SI2346864T1 (xx) |
SM (2) | SMT201300051B (xx) |
TW (1) | TWI447118B (xx) |
UY (1) | UY32006A (xx) |
WO (2) | WO2010010190A1 (xx) |
ZA (2) | ZA201100396B (xx) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
CA2708690A1 (en) * | 2009-06-26 | 2010-12-26 | Markus Braun | Process for producing cellulose beads from solutions of cellulose in ionic liquid |
JO3030B1 (ar) * | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
EP2566333A4 (en) | 2010-05-07 | 2014-04-02 | Univ Leland Stanford Junior | IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS |
US20130143915A1 (en) | 2010-07-01 | 2013-06-06 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
AR086042A1 (es) | 2011-04-28 | 2013-11-13 | Galapagos Nv | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica |
CA2880896C (en) | 2012-06-26 | 2021-11-16 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
CN103965114B (zh) * | 2013-01-28 | 2016-01-06 | 苏州泽璟生物制药有限公司 | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 |
US20160123982A1 (en) | 2013-02-04 | 2016-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
JP6435323B2 (ja) * | 2013-06-19 | 2018-12-05 | ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. | 炎症性障害の治療のための新規化合物及びその医薬組成物 |
JP6192839B2 (ja) | 2013-12-05 | 2017-09-06 | ファイザー・インク | ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、およびピロロ[2,3−d]ピリジニルアクリルアミド |
KR20160100329A (ko) | 2013-12-20 | 2016-08-23 | 3-브이 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절물질 및 이들의 조합물 |
GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
TWI679205B (zh) | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
WO2016119700A1 (en) | 2015-01-28 | 2016-08-04 | Jn Therapeutics | Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof |
CN107531694A (zh) * | 2015-04-13 | 2018-01-02 | 加拉帕戈斯股份有限公司 | 用于治疗炎性疾病的方法 |
ES2734048T3 (es) * | 2015-04-29 | 2019-12-04 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidores de Janus cinasas (JAK) |
AU2016257892A1 (en) * | 2015-05-05 | 2017-11-09 | Concert Pharmaceuticals, Inc. | Deuterated filgotinib |
CN105061420B (zh) * | 2015-06-04 | 2017-09-05 | 南京旗昌医药科技有限公司 | 一种jak抑制剂的晶型及其制备方法和应用 |
CN104987333B (zh) * | 2015-07-14 | 2017-01-11 | 苏州富士莱医药股份有限公司 | 一种Filgotinib的合成方法 |
WO2017012770A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Acid addition salts of filgotinib |
WO2017012773A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Solid forms of filgotinib free base |
WO2017012771A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Crystalline filgotinib sulfonic acid addition salts |
CN105198880B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物a晶型及其制备方法 |
CN105198877B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物g晶型及其制备方法 |
CN105218539B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物b晶型及其制备方法 |
CN105198879B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物c晶型及其制备方法 |
CN105111206B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物e晶型及其制备方法 |
CN105111207B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物d晶型及其制备方法 |
CN105198876B (zh) * | 2015-09-18 | 2017-09-29 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物h晶型及其制备方法 |
CN105198878B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物f晶型及其制备方法 |
WO2017133423A1 (zh) * | 2016-02-02 | 2017-08-10 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡啶酰胺类化合物及其应用 |
TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
CN109790158B (zh) * | 2016-07-26 | 2022-06-24 | 苏州隆博泰药业有限公司 | 作为jak抑制剂杂环化合物,该化合物的盐类及其治疗用途 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
CN107880038B (zh) * | 2016-09-30 | 2021-09-28 | 中国医药研究开发中心有限公司 | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 |
JOP20190077A1 (ar) * | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
WO2018080916A1 (en) * | 2016-10-26 | 2018-05-03 | Janssen Pharmaceutica Nv | Fused azaheterocyclic compounds and their use as ampa receptor modulators |
WO2018080917A1 (en) * | 2016-10-26 | 2018-05-03 | Janssen Pharmaceutica Nv | Fused bicylic pyridine compounds and their use as ampa receptor modulators |
EA039344B1 (ru) * | 2017-01-19 | 2022-01-17 | Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. | Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение |
CN108341814B (zh) * | 2017-01-23 | 2021-09-03 | 上海翔锦生物科技有限公司 | Jak激酶抑制剂及其应用 |
GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
MX2021015220A (es) | 2017-02-17 | 2022-12-01 | Eidos Therapeutics Inc | Procesos para preparar ácido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo. |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
WO2018189335A1 (en) | 2017-04-13 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
WO2019149244A1 (zh) * | 2018-01-31 | 2019-08-08 | 南京明德新药研发股份有限公司 | Jak抑制剂及其应用 |
KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
WO2019169135A1 (en) * | 2018-02-28 | 2019-09-06 | University Of Southern California | Compositions and methods for modulating inflammatory and degenerative disorder |
SG11202009073WA (en) | 2018-03-23 | 2020-10-29 | Eidos Therapeutics Inc | Methods of treating ttr amyloidosis using ag10 |
EP3836920A4 (en) | 2018-08-17 | 2022-04-13 | Eidos Therapeutics, Inc. | AG10 FORMULATIONS |
EP3842431B1 (en) * | 2018-08-23 | 2023-12-27 | Zhuhai United Laboratories Co., Ltd. | [1,2,4]triazolo[1,5-a]pyridine compound as jak inhibitor and application thereof |
US10815227B2 (en) | 2018-08-27 | 2020-10-27 | Cadila Healthcare Limited | Processes for the preparation of filgotinib |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
US20230391768A2 (en) * | 2018-11-07 | 2023-12-07 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
WO2021007477A1 (en) | 2019-07-11 | 2021-01-14 | E-Scape Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
WO2021023207A1 (zh) * | 2019-08-06 | 2021-02-11 | 江苏柯菲平医药股份有限公司 | Jak激酶抑制剂及其用途 |
CN111072655B (zh) * | 2019-12-30 | 2021-12-10 | 深圳市坤健创新药物研究院 | 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用 |
AU2020428591B2 (en) * | 2020-02-13 | 2024-05-23 | Zhuhai United Laboratories Co., Ltd. | Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases |
CA3166743A1 (en) * | 2020-02-21 | 2021-08-26 | Weiwei Mao | Crystalline forms of jak inhibitor and uses thereof |
AU2021267373A1 (en) | 2020-05-06 | 2022-12-08 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
CN111617318B (zh) * | 2020-05-26 | 2021-12-10 | 南京市儿童医院 | 可注射型儿童骺板再生水凝胶的制备方法 |
WO2022140527A1 (en) | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
CN114394965B (zh) * | 2021-01-29 | 2023-09-12 | 深圳市乐土生物医药有限公司 | 三唑并吡啶类化合物及其制备方法与用途 |
EP4430042A1 (en) | 2021-11-09 | 2024-09-18 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
CN113773322B (zh) * | 2021-11-10 | 2022-02-11 | 奥锐特药业(天津)有限公司 | 一种Filgotinib的制备方法 |
CN116496268A (zh) * | 2022-01-18 | 2023-07-28 | 盛世泰科生物医药技术(苏州)有限公司 | 一种含环丙酰胺化合物及其应用 |
US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
US11746108B1 (en) * | 2022-06-13 | 2023-09-05 | Apm Therapeutics 1, Inc. | Triazolopyridine polymorph A |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1156037B1 (en) | 1999-01-29 | 2004-12-01 | Chugai Seiyaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
WO2002087620A1 (fr) | 2001-04-27 | 2002-11-07 | Chugai Seiyaku Kabushiki Kaisha | Promoteurs de la chondrogenese |
US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
DE602004001676T2 (de) | 2003-02-14 | 2007-08-30 | Pfizer Products Inc., Groton | Triazolo-Pyridine als entzündungshemmende Verbindungen |
TWI221602B (en) * | 2003-07-21 | 2004-10-01 | Benq Corp | Emergent disc-withdrawing apparatus |
US20050222171A1 (en) * | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
US20070004658A1 (en) | 2004-06-21 | 2007-01-04 | Nick Vandeghinste | Method and means for treatment of osteoarthritis |
BRPI0514327A (pt) | 2004-08-18 | 2008-06-10 | Pharmacia & Upjohn Co Llc | compostos triazolopiridina |
US7524860B2 (en) | 2004-10-07 | 2009-04-28 | Pfizer Inc. | Antibacterial agents |
GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
CN103641829A (zh) * | 2006-08-30 | 2014-03-19 | 塞尔佐姆有限公司 | 作为激酶抑制剂的三唑衍生物 |
WO2008065198A1 (en) * | 2006-12-01 | 2008-06-05 | Galapagos N.V. | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases |
CL2008001626A1 (es) * | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
JP2010533680A (ja) * | 2007-07-18 | 2010-10-28 | ノバルティス アーゲー | 二環ヘテロアリール化合物およびそれらのキナーゼ阻害剤としての使用 |
WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
EA201070328A1 (ru) * | 2007-08-31 | 2010-08-30 | Мерк Сероно С.А. | Соединения триазолопиридина и их применение в качестве ингибиторов ask |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US8284682B2 (en) * | 2008-02-19 | 2012-10-09 | Qualcomm, Incorporated | Facilitating transfer of push and pull messages for remotely testing mobile devices |
US20090217316A1 (en) * | 2008-02-22 | 2009-08-27 | Binita Gupta | Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service |
PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
WO2010010186A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
DE102009000543A1 (de) * | 2009-02-02 | 2010-08-12 | Evonik Degussa Gmbh | Verfahren, Absorptionsmedien und Vorrichtung zur Absorption von CO2 aus Gasmischungen |
CA2750460C (en) * | 2009-02-02 | 2017-01-24 | Basf Se | Absorbent containing cyclic amines for removing acid gases |
WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
ES2685985T3 (es) | 2012-06-22 | 2018-10-15 | Galapagos Nv | Aminotriazolopiridina para su uso en el tratamiento de la inflamación, y composiciones farmacéuticas de la misma |
-
2009
- 2009-07-12 JO JOP/2009/0259A patent/JO3041B1/ar active
- 2009-07-22 AR ARP090102793A patent/AR072875A1/es active IP Right Grant
- 2009-07-23 TW TW098124908A patent/TWI447118B/zh active
- 2009-07-23 CL CL2009001637A patent/CL2009001637A1/es unknown
- 2009-07-24 ES ES09781073T patent/ES2406691T3/es active Active
- 2009-07-24 PL PL09781073T patent/PL2346864T3/pl unknown
- 2009-07-24 RS RS20140345A patent/RS53406B/en unknown
- 2009-07-24 EA EA201170255A patent/EA018080B1/ru unknown
- 2009-07-24 KR KR1020117004383A patent/KR101711911B1/ko active IP Right Grant
- 2009-07-24 US US13/055,936 patent/US8853240B2/en active Active
- 2009-07-24 KR KR1020117004384A patent/KR101676391B1/ko active IP Right Grant
- 2009-07-24 JP JP2011519188A patent/JP5559168B2/ja active Active
- 2009-07-24 CN CN200980129088.4A patent/CN102105471B/zh active Active
- 2009-07-24 EA EA201170257A patent/EA018587B1/ru not_active IP Right Cessation
- 2009-07-24 CN CN2009801291247A patent/CN102105472B/zh active Active
- 2009-07-24 SI SI200930582T patent/SI2346864T1/sl unknown
- 2009-07-24 NZ NZ590646A patent/NZ590646A/en unknown
- 2009-07-24 ME MEP-2014-72A patent/ME02046B/me unknown
- 2009-07-24 AU AU2009273143A patent/AU2009273143B2/en active Active
- 2009-07-24 EP EP09781072.5A patent/EP2361251B1/en active Active
- 2009-07-24 RS RS20130214A patent/RS52823B/en unknown
- 2009-07-24 UY UY0001032006A patent/UY32006A/es active IP Right Grant
- 2009-07-24 PL PL09781072T patent/PL2361251T3/pl unknown
- 2009-07-24 WO PCT/EP2009/059604 patent/WO2010010190A1/en active Application Filing
- 2009-07-24 ES ES09781072.5T patent/ES2485913T3/es active Active
- 2009-07-24 BR BRPI0916659A patent/BRPI0916659B8/pt active IP Right Grant
- 2009-07-24 SI SI200930973T patent/SI2361251T1/sl unknown
- 2009-07-24 MX MX2011000758A patent/MX2011000758A/es active IP Right Grant
- 2009-07-24 DK DK09781073.3T patent/DK2346864T3/da active
- 2009-07-24 PE PE2009000989A patent/PE20100152A1/es active IP Right Grant
- 2009-07-24 JP JP2011519189A patent/JP5480261B2/ja active Active
- 2009-07-24 CA CA2730757A patent/CA2730757A1/en not_active Abandoned
- 2009-07-24 EP EP09781073A patent/EP2346864B1/en active Active
- 2009-07-24 CA CA2730762A patent/CA2730762C/en active Active
- 2009-07-24 PT PT97810733T patent/PT2346864E/pt unknown
- 2009-07-24 BR BRPI0916862A patent/BRPI0916862B8/pt active IP Right Grant
- 2009-07-24 MX MX2011000756A patent/MX2011000756A/es active IP Right Grant
- 2009-07-24 MY MYPI20093101A patent/MY157615A/en unknown
- 2009-07-24 AU AU2009273144A patent/AU2009273144B2/en active Active
- 2009-07-24 PT PT97810725T patent/PT2361251E/pt unknown
- 2009-07-24 WO PCT/EP2009/059605 patent/WO2010010191A1/en active Application Filing
- 2009-07-24 DK DK09781072.5T patent/DK2361251T3/da active
- 2009-07-24 US US12/508,950 patent/US8242274B2/en active Active
-
2010
- 2010-12-26 IL IL210261A patent/IL210261A/en active IP Right Grant
- 2010-12-26 IL IL210262A patent/IL210262A/en active IP Right Grant
-
2011
- 2011-01-14 ZA ZA2011/00396A patent/ZA201100396B/en unknown
- 2011-01-18 DO DO2011000022A patent/DOP2011000022A/es unknown
- 2011-01-18 ZA ZA2011/00472A patent/ZA201100472B/en unknown
- 2011-02-11 MA MA33602A patent/MA32551B1/fr unknown
- 2011-02-16 CR CR20110092A patent/CR20110092A/es unknown
- 2011-02-24 CO CO11022531A patent/CO6361925A2/es active IP Right Grant
- 2011-11-30 HK HK11112985.9A patent/HK1158634A1/xx unknown
- 2011-11-30 HK HK11112990.2A patent/HK1158635A1/xx unknown
-
2012
- 2012-08-10 US US13/572,043 patent/US20120309784A1/en not_active Abandoned
-
2013
- 2013-04-23 HR HRP20130357AT patent/HRP20130357T1/hr unknown
- 2013-04-24 CY CY20131100335T patent/CY1113945T1/el unknown
- 2013-05-15 SM SM201300051T patent/SMT201300051B/xx unknown
-
2014
- 2014-06-17 SM SM201400072T patent/SMT201400072B/xx unknown
- 2014-07-15 HR HRP20140681AT patent/HRP20140681T1/hr unknown
- 2014-07-29 CY CY20141100572T patent/CY1115569T1/el unknown
- 2014-10-06 US US14/507,396 patent/US9415037B2/en active Active
-
2016
- 2016-08-15 US US15/236,578 patent/US10206907B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1158634A1 (en) | Novel compounds useful for the treatment of degenerative and inflammatory diseases | |
MX2014006980A (es) | Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk). | |
WO2009043465A3 (en) | Use of beta-endorphin as a therapeutic agent | |
WO2009043468A3 (en) | Use of corticotropin-releasing factor as a therapeutic agent | |
WO2009040048A3 (en) | Use of the c-reactive peptide as a therapeutic agent | |
EA201171306A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ | |
WO2009033793A3 (en) | Pentagastrin as a therapeutic agent | |
WO2009033732A3 (en) | Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent | |
WO2009039985A3 (en) | Therapeutic uses of urocortin ii | |
WO2009033707A3 (en) | Use of retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections | |
WO2009033739A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033800A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
MX2020003863A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. | |
WO2009049742A3 (en) | Use of melanotrophin-potentiating factor as a therapeutic agent | |
WO2009033766A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033723A3 (en) | Use of aip2 as a therapeutic agent | |
WO2009033745A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033804A3 (en) | Use of gamma- endorphin as a therapeutic agent | |
WO2009046860A3 (en) | Use of dago as a therapeutic agent | |
UA103036C2 (ru) | [1,2,4]ТРИАЗОЛО[1,5-а]ПИРИДИН, ПРИЕМЛЕМЫЙ ДЛЯ ЛЕЧЕНИЯ ДЕГЕНЕРАТИВНЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ | |
TH124149B (th) | สารประกอบชนิดใหม่ที่มีประโยชน์สำหรับการรักษาโรคที่มีการเสื่อมสภาพและ มีการอักเสบ | |
TH124149A (th) | สารประกอบชนิดใหม่ที่มีประโยชน์สำหรับการรักษาโรคที่มีการเสื่อมสภาพและมีการอักเสบ | |
TH128726B (th) | 5-เฟนิล-[1,2,4] ไตรเอโซโล [1,5-a] ไพริดิน-2-อิล คาร์บอกซามีดเป็นตัวยับยั้ง jak |